EUCTR2018-000755-40-GB进行中（未招募）1 期
A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Alglucosidase Alfa/Placebo
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject must provide signed informed consent prior to any study-related procedures being performed.
- •2. Male and female subjects are = 18 years old and weigh = 40kg at screening.
- •3. Female subjects of childbearing potential and male subjects must agree to use medically accepted methods of contraception during the study and for 90 days after the last dose of study drug.
- •4. Subject must have a diagnosis of LOPD based on documentation of one of the following:
- •a. deficiency of GAA enzyme
- •b. GAA genotyping
- •5. Subject is classified as one of the following with respect to ERT status:
- •a. ERT-experienced, defined as currently receiving standard of care ERT (alglucosidase alfa) at the recommended dose and regimen (ie, 20 mg/kg dose every 2 weeks) for = 24 months
- •b. ERT naïve, defined as never having received investigational or commercially available ERT
- •6. Subject has a sitting FVC = 30% of the predicted value for healthy adults (National Health and Nutrition Examination Survey III) at screening.
- •7. Subject performs two 6MWTs at screening that are valid, as determined by the clinical evaluator, and that meet all of the following criteria:
- •a. both screening values of 6MWD are = 75 meters
- •b. both screening values of 6MWD are = 90% of the predicted value for healthy adults
- •c. the lower value of 6MWD is within 20% of the higher value of 6MWD
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Subject has received any investigational therapy or pharmacological treatment for Pompe disease, other than alglucosidase alfa, within 30 days or 5 half lives of the therapy or treatment, whichever is longer, before Day 1 or is anticipated to do so during the study.
- •2. Subject has received gene therapy for Pompe disease.
- •3. Subject is taking any of the following prohibited medications within 30 days before Day 1:
- •miglitol (eg, Glyset)
- •miglustat (eg, Zavesca)
- •acarbose (eg, Precose or Glucobay)
- •voglibose (eg, Volix, Vocarb, or Volibo)
- •Note: None of these medications have a half-life that, when multiplied by 5, is longer than 30 days.
- •4. Subject requires the use of invasive or noninvasive ventilation support for > 6 hours per day while awake.
- •5. Subject has a hypersensitivity to any of the excipients in ATB200, alglucosidase alfa or AT2221
- •6. Subject has a medical condition or any other extenuating circumstance that may, in the opinion of the investigator or medical monitor, pose an undue safety risk to the subject or may compromise his/her ability to comply with or adversely impact protocol requirements. This includes clinical depression (as diagnosed by a psychiatrist or other mental health professional) with uncontrolled or poorly controlled symptoms.
- •7. Subject, if female, is pregnant or breastfeeding at screening.
- •8. Subject, whether male or female, is planning to conceive a child during the study.
- •9. Subject does not have documentation of diagnosis of Pompe disease and refuses to undergo genetic testing
研究者
相似试验
进行中（未招募）
1 期
A study investigating the efficacy and safety of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe disease compared withAlglucosidase Alfa/Placebo.EUCTR2018-000755-40-DEAmicus Therapeutics, Inc.110
进行中（未招募）
1 期
A study investigating the efficacy and safety of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe disease compared withAlglucosidase Alfa/Placebo.Adult Subjects With Late Onset Pompe Disease (LOPD)MedDRA version: 20.0Level: LLTClassification code 10075702Term: Pompe's disease late onsetSystem Organ Class: 100000004850EUCTR2018-000755-40-BEAmicus Therapeutics, Inc.110
进行中（未招募）
1 期
A study investigating the efficacy and safety of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe disease compared with Alglucosidase Alfa/Placebo.Adult Subjects With Late Onset Pompe Disease (LOPD)MedDRA version: 20.0 Level: LLT Classification code 10075702 Term: Pompe's disease late onset System Organ Class: 100000004850EUCTR2018-000755-40-BGAmicus Therapeutics, Inc.110
进行中（未招募）
1 期
A study investigating the efficacy and safety of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe disease compared withAlglucosidase Alfa/Placebo.Adult Subjects With Late Onset Pompe Disease (LOPD)MedDRA version: 20.0Level: LLTClassification code 10075702Term: Pompe's disease late onsetSystem Organ Class: 100000004850EUCTR2018-000755-40-DKAmicus Therapeutics, Inc.110
进行中（未招募）
1 期
A study investigating the efficacy and safety of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe disease compared withAlglucosidase Alfa/Placebo.Adult Subjects With Late Onset Pompe Disease (LOPD)MedDRA version: 20.0Level: LLTClassification code 10075702Term: Pompe's disease late onsetSystem Organ Class: 100000004850EUCTR2018-000755-40-SKAmicus Therapeutics, Inc.123